Prognosis of French COVID-19 patients with chronic liver disease: A national retrospective cohort study for 2020

J Hepatol. 2021 Oct;75(4):848-855. doi: 10.1016/j.jhep.2021.04.052. Epub 2021 May 14.

Abstract

Background & aims: The impact of chronic liver disease on outcomes in patients with COVID-19 is uncertain. Hence, we aimed to explore this association.

Methods: We explored the outcomes of all adult inpatients with COVID-19 in France, in 2020. We computed adjusted odds ratios to measure the associations between chronic liver disease, alcohol use disorders, mechanical ventilation and day-30 in-hospital mortality.

Results: The sample comprised 259,110 patients (median [IQR] age 70 (54-83) years; 52% men), including 15,476 (6.0%) and 10,006 (3.9%) patients with chronic liver disease and alcohol use disorders, respectively. Death occurred in 38,203 (15%) patients, including 7,475 (28%) after mechanical ventilation, and 2,941 (19%) with chronic liver disease. The adjusted odds ratios for mechanical ventilation and day-30 mortality were 1.54 (95% CI 1.44-1.64, p <0.001) and 1.79 (1.71-1.87, p <0.001) for chronic liver disease; 0.55 (0.47-0.64, p <0.001) and 0.54 (0.48-0.61, p <0.001) for mild liver disease; 0.64 (0.53-0.76; p <0.001) and 0.71 (0.63-0.80, p <0.001) for compensated cirrhosis; 0.65 (0.52-0.81, p <0.001) and 2.21 (1.94-2.51, p <0.001) for decompensated cirrhosis; 0.34 (0.24-0.50; p <0.001) and 1.38 (1.17-1.62, p <0.001) for primary liver cancer; and 0.82 (0.76-0.89; p <0.001) and 1.11 (1.05-1.17; p <0.001) for alcohol use disorders. Chronic viral hepatitis; non-viral, non-alcoholic chronic hepatitis; organ, including liver, transplantation, and acquired immunodeficiency syndrome were not associated with COVID-19-related death.

Conclusion: Chronic liver disease increased the risk of COVID-19-related death in France in 2020. Therapeutic effort limitation may have contributed to COVID-19-related death in French residents with a liver-related complication or an alcohol use disorder.

Lay summary: We studied the outcomes, including mechanical ventilation and day-30 mortality, of all adults with COVID-19 who were discharged from acute and post-acute care in France in 2020 (N = 259,110). Patients with mild liver disease; compensated cirrhosis; organ, including liver, transplantation; or acquired immunodepression syndrome were not at increased risk of COVID-19-related mortality. Patients with alcohol use disorders, decompensated cirrhosis, or primary liver cancer were at increased risk of COVID-19-related mortality but were less likely to receive mechanical ventilation. Our results suggest that therapeutic effort limitation may have contributed to the excess mortality in French residents with a liver-related complication or an alcohol use disorder.

Keywords: COVID-19; Respiration, Artificial; Withholding Treatment; alcohol use disorders; chronic liver disease; mortality.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Alcoholism / epidemiology
  • COVID-19 / epidemiology*
  • COVID-19 / mortality
  • COVID-19 / virology
  • Comorbidity
  • Disease Progression
  • Female
  • France / epidemiology
  • Hepacivirus*
  • Hepatitis B virus*
  • Hepatitis B, Chronic / epidemiology*
  • Hepatitis B, Chronic / virology
  • Hepatitis C, Chronic / epidemiology*
  • Hepatitis C, Chronic / virology
  • Hospital Mortality
  • Humans
  • Liver Cirrhosis / epidemiology*
  • Liver Diseases, Alcoholic / epidemiology*
  • Liver Neoplasms / epidemiology*
  • Liver Transplantation*
  • Male
  • Middle Aged
  • Prognosis
  • Respiration, Artificial
  • Retrospective Studies
  • Risk Factors
  • SARS-CoV-2*
  • Young Adult